Aurobindo Pharma Ltd’s net profit increased significantly to Rs 414 crore in the first quarter ended June 30, 2014 compared with Rs 17.46 crore in the corresponding quarter of the previous year.
The total revenue of the Hyderabad-based company had gone up 70 per cent to Rs 2,911 crore (Rs 1,715 crore).
The growth in profits and revenue was driven by higher sales of formulations. "The company delivered strong quarter on US generics injectibles, ARVs and Rest of World formulations," Aurobindo Pharma Managing Director N Govindarajan said in a release.
The company's board has approved an interim dividend at the rate of 150 per cent or Rs 1.5 per equity share of Re 1.
Aurobindo’s scrip was trading up 1.52 per cent at Rs 724.25 on the BSE.